secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2023-01-30T23:59:59+00:00
Accession:  0001485003-23-000010
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sesen Bio receives Nasdaq delisting notice; warns of dissolution if merger fails
--------------------------------------------------------------------------------

- Nasdaq notified Sesen on Jan 25, 2023 of non-compliance with $1.00 bid price; delisting unless hearing requested.
- Company plans to request Nasdaq Hearings Panel hearing to stay delisting and remain listed pending decision.
- Without pending merger with Carisma, likely path is delisting, SEC deregistration, and court-managed dissolution and liquidation.
- In dissolution, only 60%-90% of ~$140M cash (~$0.40-$0.60/share) available for initial distribution, taking 6+ months.
- Board unanimously recommends merger vote at Special Meeting on March 2, 2023; seeking reverse stock split approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000148500323000010/0001485003-23-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000148500323000010/sesn-20230125.htm
  HTML page:      https://secwatch.observer/filing/0001485003-23-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer